17β-estradiol prevents early-stage atherosclerosis in estrogen receptor-alpha deficient female mice

Amparo C Villablanca, Amy Tenwolde, Michael Lee, Melissa Huck, Shannon Mumenthaler, John C Rutledge

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Estrogen is atheroprotective and a high-affinity ligand for both known estrogen receptors, ERα and ERβ. However, the role of the ERα in early-stage atherosclerosis has not been directly investigated and is incompletely understood. ERα-deficient (ERα-/-) and wild-type (ERα+/+) female mice consuming an atherogenic diet were studied concurrent with estrogen replacement to distinguish the actions of 17β-estradiol (E2) from those of ERα on the development of early atherosclerotic lesions. Mice were ovariectomized and implanted with subcutaneous slow-release pellets designed to deliver 6 or 8∈μg/day of exogenous 17β-estradiol (E2) for a period of up to 4 months. Ovariectomized mice (OVX) with placebo pellets (E2-deficient controls) were compared to mice with endogenous E2 (intact ovaries) and exogenous E2. Aortas were analyzed for lesion area, number, and distribution. Lipid and hormone levels were also determined. Compared to OVX, early lesion development was significantly (p∈<∈0.001) attenuated by E2 with 55-64% reduction in lesion area by endogenous E 2 and >90% reduction by exogenous E2. Compared to OVX, a decline in lesion number (2- to 4-fold) and lesser predilection (~4-fold) of lesion formation in the proximal aorta also occurred with E2. Lesion size, development, number, and distribution inversely correlated with circulating plasma E2 levels. However, atheroprotection was independent of ERα status, and E2 athero-protection in both genotypes was not explained by changes in plasma lipid levels (total cholesterol, triglyceride, and high-density lipoprotein cholesterol). The ERα is not essential for endogenous/exogenous E2-mediated protection against early-stage atherosclerosis. These observations have potentially significant implications for understanding the molecular and cellular mechanisms and timing of estrogen action in different estrogen receptor (ER) deletion murine models of atherosclerosis, as well as implications to human studies of ER polymorphisms and lipid metabolism. Our findings may contribute to future improved clinical decision-making concerning the use of hormone therapy.

Original languageEnglish (US)
Pages (from-to)289-299
Number of pages11
JournalJournal of Cardiovascular Translational Research
Volume2
Issue number3
DOIs
StatePublished - Sep 2009

Fingerprint

Estrogen Receptor alpha
Estrogen Receptors
Estradiol
Atherosclerosis
Aorta
Estrogens
Hormones
Atherogenic Diet
Lipids
Estrogen Replacement Therapy
Lipid Metabolism
HDL Cholesterol
Ovary
Triglycerides
Cholesterol
Genotype
Placebos

Keywords

  • Atherosclerosis
  • Estrogen
  • Hormone
  • Lipid
  • Vascular

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Genetics
  • Genetics(clinical)
  • Molecular Medicine
  • Pharmaceutical Science

Cite this

17β-estradiol prevents early-stage atherosclerosis in estrogen receptor-alpha deficient female mice. / Villablanca, Amparo C; Tenwolde, Amy; Lee, Michael; Huck, Melissa; Mumenthaler, Shannon; Rutledge, John C.

In: Journal of Cardiovascular Translational Research, Vol. 2, No. 3, 09.2009, p. 289-299.

Research output: Contribution to journalArticle

@article{2d3ee8ee2e9f41d1ac09dc38d085e5d9,
title = "17β-estradiol prevents early-stage atherosclerosis in estrogen receptor-alpha deficient female mice",
abstract = "Estrogen is atheroprotective and a high-affinity ligand for both known estrogen receptors, ERα and ERβ. However, the role of the ERα in early-stage atherosclerosis has not been directly investigated and is incompletely understood. ERα-deficient (ERα-/-) and wild-type (ERα+/+) female mice consuming an atherogenic diet were studied concurrent with estrogen replacement to distinguish the actions of 17β-estradiol (E2) from those of ERα on the development of early atherosclerotic lesions. Mice were ovariectomized and implanted with subcutaneous slow-release pellets designed to deliver 6 or 8∈μg/day of exogenous 17β-estradiol (E2) for a period of up to 4 months. Ovariectomized mice (OVX) with placebo pellets (E2-deficient controls) were compared to mice with endogenous E2 (intact ovaries) and exogenous E2. Aortas were analyzed for lesion area, number, and distribution. Lipid and hormone levels were also determined. Compared to OVX, early lesion development was significantly (p∈<∈0.001) attenuated by E2 with 55-64{\%} reduction in lesion area by endogenous E 2 and >90{\%} reduction by exogenous E2. Compared to OVX, a decline in lesion number (2- to 4-fold) and lesser predilection (~4-fold) of lesion formation in the proximal aorta also occurred with E2. Lesion size, development, number, and distribution inversely correlated with circulating plasma E2 levels. However, atheroprotection was independent of ERα status, and E2 athero-protection in both genotypes was not explained by changes in plasma lipid levels (total cholesterol, triglyceride, and high-density lipoprotein cholesterol). The ERα is not essential for endogenous/exogenous E2-mediated protection against early-stage atherosclerosis. These observations have potentially significant implications for understanding the molecular and cellular mechanisms and timing of estrogen action in different estrogen receptor (ER) deletion murine models of atherosclerosis, as well as implications to human studies of ER polymorphisms and lipid metabolism. Our findings may contribute to future improved clinical decision-making concerning the use of hormone therapy.",
keywords = "Atherosclerosis, Estrogen, Hormone, Lipid, Vascular",
author = "Villablanca, {Amparo C} and Amy Tenwolde and Michael Lee and Melissa Huck and Shannon Mumenthaler and Rutledge, {John C}",
year = "2009",
month = "9",
doi = "10.1007/s12265-009-9103-z",
language = "English (US)",
volume = "2",
pages = "289--299",
journal = "Journal of Cardiovascular Translational Research",
issn = "1937-5387",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - 17β-estradiol prevents early-stage atherosclerosis in estrogen receptor-alpha deficient female mice

AU - Villablanca, Amparo C

AU - Tenwolde, Amy

AU - Lee, Michael

AU - Huck, Melissa

AU - Mumenthaler, Shannon

AU - Rutledge, John C

PY - 2009/9

Y1 - 2009/9

N2 - Estrogen is atheroprotective and a high-affinity ligand for both known estrogen receptors, ERα and ERβ. However, the role of the ERα in early-stage atherosclerosis has not been directly investigated and is incompletely understood. ERα-deficient (ERα-/-) and wild-type (ERα+/+) female mice consuming an atherogenic diet were studied concurrent with estrogen replacement to distinguish the actions of 17β-estradiol (E2) from those of ERα on the development of early atherosclerotic lesions. Mice were ovariectomized and implanted with subcutaneous slow-release pellets designed to deliver 6 or 8∈μg/day of exogenous 17β-estradiol (E2) for a period of up to 4 months. Ovariectomized mice (OVX) with placebo pellets (E2-deficient controls) were compared to mice with endogenous E2 (intact ovaries) and exogenous E2. Aortas were analyzed for lesion area, number, and distribution. Lipid and hormone levels were also determined. Compared to OVX, early lesion development was significantly (p∈<∈0.001) attenuated by E2 with 55-64% reduction in lesion area by endogenous E 2 and >90% reduction by exogenous E2. Compared to OVX, a decline in lesion number (2- to 4-fold) and lesser predilection (~4-fold) of lesion formation in the proximal aorta also occurred with E2. Lesion size, development, number, and distribution inversely correlated with circulating plasma E2 levels. However, atheroprotection was independent of ERα status, and E2 athero-protection in both genotypes was not explained by changes in plasma lipid levels (total cholesterol, triglyceride, and high-density lipoprotein cholesterol). The ERα is not essential for endogenous/exogenous E2-mediated protection against early-stage atherosclerosis. These observations have potentially significant implications for understanding the molecular and cellular mechanisms and timing of estrogen action in different estrogen receptor (ER) deletion murine models of atherosclerosis, as well as implications to human studies of ER polymorphisms and lipid metabolism. Our findings may contribute to future improved clinical decision-making concerning the use of hormone therapy.

AB - Estrogen is atheroprotective and a high-affinity ligand for both known estrogen receptors, ERα and ERβ. However, the role of the ERα in early-stage atherosclerosis has not been directly investigated and is incompletely understood. ERα-deficient (ERα-/-) and wild-type (ERα+/+) female mice consuming an atherogenic diet were studied concurrent with estrogen replacement to distinguish the actions of 17β-estradiol (E2) from those of ERα on the development of early atherosclerotic lesions. Mice were ovariectomized and implanted with subcutaneous slow-release pellets designed to deliver 6 or 8∈μg/day of exogenous 17β-estradiol (E2) for a period of up to 4 months. Ovariectomized mice (OVX) with placebo pellets (E2-deficient controls) were compared to mice with endogenous E2 (intact ovaries) and exogenous E2. Aortas were analyzed for lesion area, number, and distribution. Lipid and hormone levels were also determined. Compared to OVX, early lesion development was significantly (p∈<∈0.001) attenuated by E2 with 55-64% reduction in lesion area by endogenous E 2 and >90% reduction by exogenous E2. Compared to OVX, a decline in lesion number (2- to 4-fold) and lesser predilection (~4-fold) of lesion formation in the proximal aorta also occurred with E2. Lesion size, development, number, and distribution inversely correlated with circulating plasma E2 levels. However, atheroprotection was independent of ERα status, and E2 athero-protection in both genotypes was not explained by changes in plasma lipid levels (total cholesterol, triglyceride, and high-density lipoprotein cholesterol). The ERα is not essential for endogenous/exogenous E2-mediated protection against early-stage atherosclerosis. These observations have potentially significant implications for understanding the molecular and cellular mechanisms and timing of estrogen action in different estrogen receptor (ER) deletion murine models of atherosclerosis, as well as implications to human studies of ER polymorphisms and lipid metabolism. Our findings may contribute to future improved clinical decision-making concerning the use of hormone therapy.

KW - Atherosclerosis

KW - Estrogen

KW - Hormone

KW - Lipid

KW - Vascular

UR - http://www.scopus.com/inward/record.url?scp=68749103250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68749103250&partnerID=8YFLogxK

U2 - 10.1007/s12265-009-9103-z

DO - 10.1007/s12265-009-9103-z

M3 - Article

VL - 2

SP - 289

EP - 299

JO - Journal of Cardiovascular Translational Research

JF - Journal of Cardiovascular Translational Research

SN - 1937-5387

IS - 3

ER -